A2B395 / A2 Biotherap - LARVOL DELTA

Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT06682793 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

CAR T-Cell Therapy • Metastases • Oncology • Solid Tumor • EGFR

DENALI-1: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: A2 Biotherapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod Technology Platform (Businesswire) - "A2 Biotherapeutics...announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that includes The Column Group and Samsara BioCapital. Proceeds will fund the company’s three clinical development programs and advancement of its pipeline of CAR-T cell therapies based on its proprietary Tmod platform technology."

Financing • Solid Tumor